Quantitation of Humalog insulin by reversed-phase high-performance liquid chromatography

Journal of Diabetes Science and Technology

Volumn 1, Issue 4, 2007, Pages 603-607

  Munsick, Carey ^a   Murray, Robert ^b   Dziubla, Tom ^b   Lowman, Anthony M ^b   Joseph, Jeffrey I ^a   Torjman, Marc C ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Drexel University   (United States)

^c Division of Female Pelvic Medicine and Reconstructive Surgery   (United States)

Author keywords

Drug delivery systems; HPLC assay; Humalog; Insulin; Lispro

Indexed keywords

EID: 84876572084     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680700100420     Document Type: Article

References (11)

1. Gin H, Renard E, Melki V, Boivin S, Schaepelynck-Belicar P, Guerci B, Selam JL, Brun JM, Riveline J P, Estour B, Catargi B; EVADIAC Study Group. Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: the EVADIAC experience. Diabetes Metab. 2003 Dec; 29(6):602-7.
2. Renard E, Souche C, Jacques-Apostol D, Lauton D, Gibert-Boulet F, Costalat G, Bringer J, Jaffiol C. Improved stability of insulin delivery from implanted pumps using a new preparation process for infused insulin. Diabetes Care. 1999 Aug; 22(8):1371-2.
3. Boivin S, Belicar P, Melki V. Assessment of in vivo stability of a new insulin preparation for implantable insulin pumps. A randomized multicenter prospective trial. EVADIAC Group. Evaluation Dans le diabete du Traitement par Implants Actifs. Diabetes Care. 1999 Dec; 22(12):2089-90.
4. Demirdjian S, Bardin C, Savin S, Zirinis P, Chast F, Slama G, Selam JL. Lispro insulin is suitable for external pumps but not for implantable pumps. Diabetes Care. 1998 May; 21(5):867-8.
5. Scavini M, Hammarberg B, Dosio F, Torri M, Petrella G, Galimberti G, Vai S, Fazio F, Pozza G. A method for assessing catheter patency in implanted pumps for long-term intraperitoneal insulin delivery. Artif Organs. 1997 May; 21(5):405-8.
6. Poulsen C. Langkjaer L. Worsoe C. Precipitation of insulin products used for continuous subcutaneous insulin infusion. Diabetes Technology & Therapeutics. 7(1):142-50, 2005.
7. Lougheed WD, Woulfe-Flanagan H, Clement JR, Albisser AM. Insulin aggregation in artifcial delivery systems. Diabetologia. 1980 Jul; 19(1):1-9.
8. Lougheed WD, Zinman B, Strack TR, Janis LJ, Weymouth AB, Bernstein EA, Korbas AM, Frank BH. Stability of insulin lispro in insulin infusion systems. Diabetes Care. 1997 Jul; 20(7):1061-5.
9. Wright A W D, Little AJ. Cannula occlusion of insulin lispro and insulin infusion systems. Diabetes Care. 1998 May; 21(5):874-5.
10. Wolpert HA, Faradji RN, Bonner-Weir S, Lipes MA. Metabolic decompensation in pump users due to lispro insulin. BMJ. 2002 May 25;324(7348):1253.
11. De Felippis MR, Bell MA, Heyob JA, Storms SM. In vitro stability of insulin lispro in continuous subcutaneous insulin infusion. Diabetes Technol Ther. 2006 Jun; 8(3):358-68.